Track topics on Twitter Track topics that are important to you
Hua Medicine of Beijing raised $110 million in a Hong Kong IPO at a valuation of $1.1 billion, the second pre-revenue China biopharma to list on the exchange. The offering was expected to bring in $200 million, but market sentiment has become cautious. Hua will complete clinical trials of its lead drug candidate, dorzagliatin, a GKA activator, in 2019. Dorzagliatin is in Phase III China trials to treat type 2 diabetes as a monotherapy and in combination with metformin. More details....
Stock Symbol: (HK: 2552)
Share this with colleagues:
Original Article: Hua Medicine Stages $110 Million Hong Kong IPO at $1.1 Billion ValuationNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...